Aclaris Therapeutics Appoints Robert Doody as Vice President, Investor Relations

Aclaris Therapeutics

WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced that it has appointed Robert A. Doody Jr. as Vice President, Investor Relations.

“We are very excited that we continue further strengthening our team through the addition of experienced industry veterans with successful track records,” said Neal Walker, Chief Executive Officer of Aclaris. “Bob brings to Aclaris considerable experience leading investor relations programs across a number of various therapeutic sectors.”

Mr. Doody has nearly 20 years of biotechnology industry experience leading investor relations programs, most recently serving as Vice President of Investor Relations at Provention Bio. Prior to that, Mr. Doody led investor relations at Idera Pharmaceuticals, and ViroPharma Incorporated until its acquisition by Shire Pharmaceuticals.

Prior to joining the industry, Mr. Doody began his career at the healthcare communications firm, Dorland Sweeney Jones in Philadelphia, PA. He received his Bachelor of Arts degree in Communications from Rowan University. Mr. Doody also served honorably in the United States Navy.

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News.

Thanks for visiting! Looking for some Chester County pride? We got you covered! Shop our MyChesCo store and show your love for Chester County, Pennsylvania. We got shirts, hats, and more – all with a unique ChesCo flair. Plus, proceeds from each purchase helps support our mission of bringing reliable information and resources to the people of Chester County.